Related Experiment Video

Updated: Jan 25, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

370

Targeting tumor neovasculature in non-small-cell lung cancer

Athanasios G Pallis1, Konstantinos N Syrigos

  • 1Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece. agpallis@gmail.com

Critical Reviews in Oncology/Hematology
|November 20, 2012
PubMed

Insights

Targeted therapies for non-small cell lung cancer (NSCLC) focus on inhibiting angiogenesis, the process tumors use to grow blood vessels. Bevacizumab, an anti-vascular endothelial growth factor (VEGF) therapy, is approved for metastatic NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Tumorigenesis involves molecular mechanisms that can be targeted for novel therapies.
  • Angiogenesis, crucial for tumor growth, is a key research area in non-small cell lung cancer (NSCLC).
  • The vascular endothelial growth factor (VEGF) pathway is central to tumor angiogenesis.

Purpose of the Study:

  • To review the current status of antiangiogenic therapies for NSCLC.
  • To discuss challenges and future directions in antiangiogenic therapy for NSCLC.

Main Methods:

  • Review of clinical strategies targeting tumor vasculature development.
  • Analysis of agents targeting the VEGF pathway, including monoclonal antibodies and tyrosine kinase inhibitors.
  • Examination of approved and investigational antiangiogenic agents for NSCLC.

Main Results:

  • Bevacizumab, a monoclonal antibody against VEGF, is approved for metastatic NSCLC in combination with chemotherapy.
  • Several other antiangiogenic agents targeting VEGF are in Phase III clinical investigation.
  • Predictive biomarkers and resistance mechanisms require further elucidation.

Conclusions:

  • Antiangiogenic therapies targeting the VEGF pathway are a significant advancement in NSCLC treatment.
  • Further research is needed to optimize patient selection and overcome resistance to these therapies.

More Related Videos

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.3K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K